Table IV.
Antibody response to SARS-CoV-2 vaccine in PAD patients by clinical subtype
| Variable | Primary PAD (n = 52) |
All primary PAD (n = 52) (total) | Secondary PAD (n = 10) (total) | P | |||
|---|---|---|---|---|---|---|---|
| Mild (n = 12) | Moderate (n = 21) | Severe (n = 19) | P | ||||
| Anti-spike antibody, U/mL (geometric mean [95% CI], n) | 2,003 (677.1-5,922) n = 12 | 321.8 (81-1,279) n = 21 | 35.7 (7.7-166.2) n = 19 | .001 | 219.8 (90.1-536.2) n = 52 | 13.4 (1.1-170.8) n = 10 | .02 |
| Neutralization (pNT50) (geometric mean [95% CI], n) | 389 (103.8-1,458) n = 8 | 90.2 (35.3-230.1) n = 11 | 43.4 (16.6-113.7) n = 13 | .01 | 96.6 (52.0-179.3) n = 32 | 30.9 (6.2-154.4) n = 5 | .17 |
| Anti-receptor binding domain antibody (IgT), U/mL (geometric mean [95% CI], n) | 25.6 (8.4-78.2) n = 8 | 7.1 (1.1-47.5) n = 11 | 0.3 (0.02-4.9) n = 12 | .01 | 3.0 (0.8-11.3) n = 31 | 0.1 (0.0-58.5) n = 5 | .09 |
CI, confidence interval; PAD, predominant antibody deficiency.